diabetes drugs

Diabetes drug may fight lethal cancer

harminka — Thu, 24 Sep 2009 12:29:57 -0500

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

Diabetes drug kills cancer stem cells

harminka — Mon, 14 Sep 2009 11:30:13 -0500

In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone, apparently by targeting cancer stem cells, report Harvard Medical School researchers in the Sept. 14 advance online Cancer Research.

Pancreatitis in Patients taking Byetta, FDA Warns

erku — Mon, 18 Aug 2008 18:10:38 -0500

This alert about Amylin's Byetta is from 2007. Then it was only an FDA alert, but today FDA updated the information about Amylin's Byetta and warns of the diabetes drug, saying that Byetta has a potential risk for pancreatitis.

Protein target for diabetes drug regulates blood pressure

harminka — Tue, 04 Mar 2008 13:26:25 -0600

University of Iowa researchers have identified a molecular pathway in blood vessels that controls blood pressure and vascular function and may help explain why certain drugs for type II diabetes also appear to lower patients' blood pressure. The study is published in the March 5 issue of Cell Metabolism.

Blood pressure control may explain diabetes drugs' benefit

harminka — Tue, 04 Mar 2008 13:05:14 -0600

Drugs known as thiazolidinediones (TZDs), which are used to treat type 2 diabetes, seem to come with an added side benefit: They lower blood pressure. Now, researchers reporting in the March issue of Cell Metabolism, a publication of Cell Press, provide new evidence as to why.

Clinical trials for diabetes drugs measure outcomes important to patients

harminka — Fri, 28 Sep 2007 14:36:00 -0500

Most clinical trials for new diabetes drugs do not consider the impact medication will have on a patient’s quality of life or other outcomes that are important to patients, such as the risk of developing complications associated with diabetes, according to a Mayo Clinic commentary in the current issue of The Lancet.

Diabetes Drug Kills Some Cancer Cells

harminka — Wed, 15 Aug 2007 05:30:06 -0500

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53. Results from current studies in mice may result in new therapies for a subset of human cancers that tend to be aggressive and resistant to existing treatments.

Diabetes drugs double risk of heart failure: study

Dinka — Fri, 27 Jul 2007 11:34:48 -0500

Two popular drugs used to treat late-onset diabetes may double the risk of heart failure, a new study has found. Researchers who analysed data on 78,000 patients who took Avandia or Actos to treat type 2 diabetes found that it increased the risk of heart failure by up to 100 per cent.

Diabetes drugs increase risk of heart failure

harminka — Fri, 27 Jul 2007 02:26:47 -0500

A class of drugs commonly used to treat type 2 diabetes may double the risk of heart failure, according to a new analysis by researchers at Wake Forest University School of Medicine and colleagues.

Top-10 comparison of diabetes drugs give metformin top grade

harminka — Thu, 26 Jul 2007 00:58:44 -0500

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.

Red blood cells talk to platelets, with implications for diabetes

harminka — Mon, 16 Jul 2007 12:53:17 -0500

Amid growing indications that the traditional image of red blood cells (RBCs) falls short of reality, chemists are reporting evidence that RBCs are key participants in a communication system among cells in the bloodstream.

Diabetes drug Avandia can cause heart risks

Dinka — Fri, 13 Jul 2007 11:24:53 -0500

A surprising analysis revealed possible heart risks from the blockbuster diabetes drug Avandia, reports of side effects to federal regulators tripled.